A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Cresemba to Evaluate Safety and Effectiveness in Patients With Invasive Aspergillosis or Invasive Mucormycosis in Korea

Trial Information
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational

The purpose of this study is to observe safety and effectiveness of Cresemba in patients with invasive Aspergillosis or invasive Mucormycosis in Korea during the post-marketing surveillance period as required by Ministry of Food and Drug Safety (MFDS).

Am I eligible for this trial?
Participation Requirements
Minimum Age:
Healthy Volunteers:

• Patients aged 19 years or older

• Patients with proven or suspected diagnosis of invasive Aspergillosis or invasive Mucormycosis.

• Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Where is this trial taking place?
Other Locations
Republic of Korea
Pfizer Korea
Who do I contact about this trial?
Pfizer CT.gov Call Center
When is this trial taking place?
Start Date: September 9, 2021
Estimated Completion Date: January 30, 2026
How many participants will be in this trial?
Target number of participants: 600
What other conditions are being studied in this trial?

This content was sourced from clinicaltrials.gov

Periareolar Approach in Minimally Invasive Cardiac Surgery; New Trend.
Status:Not yet recruiting
Start Date:February 2021
Study Type:Procedure
Phase: Not Applicable